Education History
| Undergraduate |
Sardar Patel Vidyalaya |
AISSC |
|---|---|---|
| Professional Medical |
University of Delhi |
MD |
| Internship |
University of Delhi Hospital |
Intern |
| Residency |
Post Graduate Institute of Medical Education and Research |
Junior Resident |
| Internship |
Michael Reese Hospital |
Intern |
| Residency |
Michael Reese Hospital |
Resident |
| Fellowship |
University of Texas Health Science Center |
Fellow |
| Graduate Training |
University of Massachusetts |
MBA |
Selected Publications
Journal Article
- Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade J (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 73(6), 1241-52. (Read full article)
- Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer chemotherapy and pharmacology, 75(1), 87-95. (Read full article)
- Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth B (2014). Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of clinical oncology, 32(2), 129-60. (Read full article)
- Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla K (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 28(11), 2155-64. (Read full article)
- Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla K (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 29(6), 1267-78. (Read full article)
- Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman J (2014). Ceritinib in ALK-rearranged non-small-cell lung cancer. The New England journal of medicine, 370(13), 1189-97. (Read full article)
- Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands), 85(3), 429-34. (Read full article)
- Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clinical cancer research, 20(2), 480-9. (Read full article)
- Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick S (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clinical cancer research, 20(17), 4584-97. (Read full article)
- Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla K (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular cancer therapeutics, 13(5), 1142-54. (Read full article)
- Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla K (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular cancer therapeutics, 13(10), 2315-27. (Read full article)
- Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D (2014). Colon cancer, version 3.2014. Journal of the National Comprehensive Cancer Network, 12(7), 1028-59. (Read full article)
- Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla K (2014). Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget, 5(14), 5637-50. (Read full article)
Abstract
- Wade JL , Dakhil SR , Baron AD , Rottey S , Millard FE , Daugaard G , Machiels J , Conkright WA, Sharma S , Soetekouw P , Yachnin J , Sengeløv L , van Veldhuizen P , Agarwala SS , Quyen Nguyen TX , Chadjaa M , Maison-Blanche (2012). A QTc study of cabazitaxel in patients with advanced solid tumors.
- Shaw AT, Camidge DR, Felip E, Sharma S , Tan DSW, Kim DW , De Pas T , Vansteenkiste JF , Santor A, Liu G , Chow L , Goldwasser M , Lau Y, Boral AL, Mehra (2012). Results of the first-in-human Phase I study of the ALK inhibitor LDK378 in advanced malignancies.